Pharsight

Sernivo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9775851 PRIMUS PHARMS Topical formulations comprising a steroid
Aug, 2030

(6 years from now)

US9364485 PRIMUS PHARMS Topical formulations comprising a steroid
Aug, 2030

(6 years from now)

US9655907 PRIMUS PHARMS Topical formulations comprising a steroid
Aug, 2030

(6 years from now)

US10179137 PRIMUS PHARMS Topical formulations comprising a steroid
Aug, 2030

(6 years from now)

US9433630 PRIMUS PHARMS Topical formulations comprising a steroid
Aug, 2030

(6 years from now)

US9877974 PRIMUS PHARMS Topical formulations comprising a steroid
Aug, 2030

(6 years from now)

US9439911 PRIMUS PHARMS Topical formulations comprising a steroid
Aug, 2030

(6 years from now)

Sernivo is owned by Primus Pharms.

Sernivo contains Betamethasone Dipropionate.

Sernivo has a total of 7 drug patents out of which 0 drug patents have expired.

Sernivo was authorised for market use on 05 February, 2016.

Sernivo is available in spray;topical dosage forms.

Sernivo can be used as treatment of plaque psoriasis.

The generics of Sernivo are possible to be released after 31 August, 2030.

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Feb 05, 2019

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using BETAMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 05 February, 2016

Treatment: Treatment of plaque psoriasis

Dosage: SPRAY;TOPICAL

How can I launch a generic of SERNIVO before it's drug patent expiration?
More Information on Dosage

SERNIVO family patents

Family Patents